Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Nanobiotix Appoints Thierry Otin as Head of Manufacturing and Supply

Abstract:
NANOBIOTIX (Euronext: NANO-ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announced the appointment of Thierry Otin as Head of Manufacturing and Supply. The appointment strengthens the Nanobiotix organisation, Mr Otin will be responsible for the manufacturing plans to move the lead product, NBTXR3, from clinical trials into full commercialization as from 2016.

Nanobiotix Appoints Thierry Otin as Head of Manufacturing and Supply

Paris, France | Posted on April 15th, 2014

Prior to joining Nanobiotix, Mr Otin was the Quality Site Manager (EU Sterile) at Roche and before then, he worked at LFB Biotechnologies as the Head Pharmacist (Pharmaceutical Qualified Person) and Quality Director. Prior to this, he worked in QA/GMP and manufacturing with world class companies including, Schering CISBiointernational, Institut de Formation des Industries de Santé (IFIS), UCB, Delagrange and Rhône-Poulenc (Roger Bellon and Specia). He has a degree in biology and has a doctorate in Pharmacy from the University of Strasbourg.

Laurent Levy, CEO of Nanobiotix said: "Thierry Otin joins us having had over 30 years' experience in the global pharmaceutical industry which includes 12+ years' experience of injectable drug production management and 11+ years in QA senior compliance management. This wealth of expertise will be invaluable to us as we move our lead product to commercialization. We welcome him to the team."

####

About Nanobiotix
Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Company’s first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat a wide variety of cancers via multiple routes of administration.
Nanobiotix’s lead product NBTXR3, based on NanoXray, is currently under clinical development for soft tissue sarcoma and locally advanced head and neck cancer. The Company, based in Paris, France, has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.

Nanobiotix is listed on the regulated market of Euronext Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP).

Issued for and on behalf of Nanobiotix by Instinctif Partners.

For more information, please click here

Contacts:
Sarah Gaubert
Head of Communication
and Public Affairs
+33 (0)1 40 26 07 55


Media Relations
France - NewCap
Annie-Florence Loyer/ Nadège Le Lezec
+33 (0)6 88 20 35 59
/

Financial communication and investors relations
NewCap.
Louis-Victor Delouvrier / Emmanuel Huynh
+33 (0)1 44 71 98 53


Instinctif Partners
Melanie Toyne Sewell / Katherine Lynch / Donia Al Saffar
+44 (0) 207 457 2020

Copyright © Nanobiotix

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Light pulses control graphene's electrical behavior: Finding could allow ultrafast switching of conduction, and possibly lead to new broadband light sensors August 1st, 2014

President Obama Meets U.S. Laureates of 2014 Kavli Prizes August 1st, 2014

Stanford researchers seek 'Holy Grail' in battery design: Pure lithium anode closer to reality with development of protective layer of interconnected carbon domes August 1st, 2014

Air Force’s 30-year plan seeks 'strategic agility' August 1st, 2014

Nanomedicine

Taking the guesswork out of cancer therapy: New molecular test kit predicts patient’s survival and drug response August 1st, 2014

Arrowhead to Report Fiscal 2014 Third Quarter Financial Results- Conference Call Scheduled for Tuesday, August 12, 2014 - July 31st, 2014

New imaging agent provides better picture of the gut July 30th, 2014

Zenosense, Inc. July 29th, 2014

Announcements

Light pulses control graphene's electrical behavior: Finding could allow ultrafast switching of conduction, and possibly lead to new broadband light sensors August 1st, 2014

President Obama Meets U.S. Laureates of 2014 Kavli Prizes August 1st, 2014

Stanford researchers seek 'Holy Grail' in battery design: Pure lithium anode closer to reality with development of protective layer of interconnected carbon domes August 1st, 2014

Air Force’s 30-year plan seeks 'strategic agility' August 1st, 2014

Appointments/Promotions/New hires/Resignations/Deaths

ACS Biomaterials Science & Engineering™: Brand-new journal names editor July 29th, 2014

Organometallics welcomes new editor-in-chief: Paul Chirik, Ph.D. July 22nd, 2014

NSS Pays Tribute to Space Pioneer Frederick I. Ordway III July 7th, 2014

Harris & Harris Group Announces Changes to Its Legal Department June 9th, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE